Overview

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Status:
Completed

Trial end date:
2019-01-10

Target enrollment:

Participant gender:

Summary

This protocol is a follow-up for patients receiving continuation of OPN-305 monotherapy treatment or combination treatment with azacitidine after completion of the dose confirming, dose expansion and HMA naïve parts of the main study OPN-305-106.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Opsona Therapeutics Ltd.

Collaborators:

H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Montefiore Medical Center
New York Presbyterian Hospital